Sarah Lowndes - Publications
Affiliations: | 2003-2006 | University of Oxford, Oxford, United Kingdom |
Year | Citation | Score | |||
---|---|---|---|---|---|
2009 | Lowndes SA, Sheldon HV, Cai S, Taylor JM, Harris AL. Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms. Microvascular Research. 77: 314-26. PMID 19323979 DOI: 10.1016/j.mvr.2009.01.003 | 0.41 | |||
2008 | Lowndes SA, Adams A, Timms A, Fisher N, Smythe J, Watt SM, Joel S, Donate F, Hayward C, Reich S, Middleton M, Mazar A, Harris AL. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7526-34. PMID 19010871 DOI: 10.1158/1078-0432.CCR-08-0315 | 0.402 | |||
2006 | Lowndes SA, Harris AL. The role of copper in tumour angiogenesis. Journal of Mammary Gland Biology and Neoplasia. 10: 299-310. PMID 16924372 DOI: 10.1007/s10911-006-9003-7 | 0.442 | |||
2006 | Lowndes SA, Adams A, Timms A, Middleton M, Hayward C, Reich SD, Mazar AP, Harris AL. Phase I study of ATN-224 in patients (pts) with advanced solid tumours Journal of Clinical Oncology. 24: 2065-2065. DOI: 10.1200/jco.2006.24.18_suppl.2065 | 0.388 | |||
2006 | Doñate F, Lowndes S, Juarez J, Manuia M, Smith E, Liu N, Hayward C, Batuman O, Harris A, Mazar A. 132 POSTER Translation of in vitro markers of the anti-angiogenic and anti-tumor activity of the SOD1 inhibitor ATN-224 to clinical trials European Journal of Cancer Supplements. 4: 43. DOI: 10.1016/s1359-6349(06)70138-0 | 0.302 | |||
2004 | Lowndes SA, Harris AL. Copper chelation as an antiangiogenic therapy Oncology Research. 14: 529-539. PMID 15666995 DOI: 10.3727/0965040042707952 | 0.443 | |||
Show low-probability matches. |